Qiming Corporate GP VI, Ltd. is a corporate entity that reports beneficial ownership of shares in Alamar Biosciences, Inc. (ALMR) under U.S. securities law. It has submitted 1 SEC insider filing since 2026, most recently in April 2026.
Every role Qiming Corporate GP VI, Ltd. has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Alamar Biosciences, Inc. (ALMR)1 filingUpdated Aug 31, 2026
Qiming Corporate GP VI, Ltd. files SEC Form 4 reports at Alamar Biosciences, Inc. (ALMR). 1 SEC Form 4 filing on record, dated 22 April 2026.
Every recent SEC Form 4 transaction Qiming Corporate GP VI, Ltd. has reported, most recent first.
InsiderAlpha's records for Qiming Corporate GP VI, Ltd. go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Qiming Corporate GP VI, Ltd. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Qiming Corporate GP VI, Ltd. is a corporate entity of Alamar Biosciences, Inc. (ALMR). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
The only primary Form 4 on record is dated 22 April 2026.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial